Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Pharm Res ; 37(10): 201, 2020 Sep 24.
Article in English | MEDLINE | ID: mdl-32968862

ABSTRACT

PURPOSE: As per the Japanese or SUPAC guidance to maintain formulation composition similarity across tablet strengths, the coating should be applied based on the core tablet surface area or weight, respectively. These two coating approaches were compared by evaluating protective effects of coating on the light stability of three model compounds. METHODS: Core tablets of three light sensitive drugs, nifedipine, rosuvastatin calcium, and montelukast sodium were coated either with PVA-based Opadry® II white or Opadry® II beige. The coated tablets were exposed to light up to three ICH cycles. RESULTS: For Opadry® II white, the surface area based coating provided consistent light protection across tablet strengths when the coating amount was more than 0.1 mg/mm2 compared to that based on core tablet weights. For Opadry® II beige, both approaches gave comparable and better light protection due to presence of iron oxides. The light protection by Opadry® II white could be because of physical barrier of coating, which was uniform across the strengths when it was based on core tablet surface area. CONCLUSION: For a routine tablet formulation development with Opadry color coating, it does not matter whether the coating is applied based on the core tablet surface area or weight.


Subject(s)
Drug Compounding/methods , Tablets/chemistry , Acetates , Chemistry, Pharmaceutical , Cyclopropanes , Drug Stability , Humans , Nifedipine , Photophobia , Quinolines , Rosuvastatin Calcium , Sulfides
2.
Pharm Dev Technol ; 25(8): 1010-1017, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32432492

ABSTRACT

A quality by design (QbD) approach was used for a polyvinyl alcohol (PVA)-based coating to develop a 'look-alike' placebo tablet, which can match the glossiness (shine) of an innovator tablet. Critical coating parameters such as exhaust temperature, drying capacity, solid concentration in coating dispersion, and plasticizer concentration were studied using a full factorial design of experiment (DoE). Total of 20 experimental coating runs was executed on a pilot scale using a perforated pan coater. Coated tablets were evaluated visually against the innovator product by a panel of 13 volunteers using an individual questionnaire about the tablet appearance. The tablet appearance included factors such as tablet surface shine, surface roughness, and logo bridging. These data were analyzed using JMP software. Solid concentration in coating dispersion and drying capacity were found to be the key contributing parameters for tablet surface shine. Human observations were more discerning in spotting subtle differences in tablet appearance than Munsell evaluation. By the judicious selection of a solid concentration in coating dispersion and drying conditions, a look-alike placebo tablet was successfully developed. Change in tablet shape or size did not affect the tablet shine. However, replacement of PVA-based coating with hydroxypropyl methylcellulose (HPMC)-based coating resulted in reduced shine irrespective of tablet shape and size.


Subject(s)
Tablets/chemistry , Chemistry, Pharmaceutical/methods , Drug Compounding/methods , Excipients/chemistry , Humans , Hypromellose Derivatives/chemistry , Plasticizers/chemistry , Polyvinyl Alcohol/chemistry , Surface Properties , Temperature
3.
Pharm Dev Technol ; 24(10): 1250-1257, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31437082

ABSTRACT

Using instrumented roll technology, statistical models relating process parameters such as hydraulic pressure, roll speed and screw speed of Vector TF mini roller compactor to ribbon normal stress and density were developed for placebo blends. Normal stress was found to be directly proportional to hydraulic pressure, roll speed and inversely to screw to roll speed ratio. A power-law relationship between ribbon density and normal stress was observed for placebo blends. Models developed for placebo were found to predict ribbon densities of active blends with good accuracy. Standard optimization of roller compaction process parameters involves the investment of a large amount of time and active ingredient. These models can, therefore, be utilized to predict starting instrument settings required to generate a ribbon of desired solid fraction during early-stage development where material availability & time is limited.


Subject(s)
Drug Compounding/instrumentation , Models, Statistical , Placebos/chemistry , Carboxymethylcellulose Sodium/chemistry , Cellulose/chemistry , Drug Compounding/methods , Drug Compounding/statistics & numerical data , Lactose/chemistry , Powders , Pressure , Silicon Dioxide/chemistry , Stearic Acids/chemistry
4.
Int J Pharm ; 541(1-2): 253-260, 2018 Apr 25.
Article in English | MEDLINE | ID: mdl-29481947

ABSTRACT

Form changes during drug product processing can be a risk to the final product quality in terms of chemical stability and bioavailability. In this study, online Raman spectroscopy was used to monitor the form changes in real time during high shear wet granulation of Compound A, a highly soluble drug present at a high drug load in an extended release formulation. The effect of water content, temperature, wet massing time and drying technique on the degree of drug transformation were examined. A designed set of calibration standards were employed to develop quantitative partial least square regression models to predict the concentration of each drug form during both wet granulation and the drying process. Throughout all our experiments we observed complex changes of the drug form during granulation, manifest as conversions between the initial non-solvated form of Compound A, the hemi-hydrate form and the "apparent" amorphous form (dissolved drug). The online Raman data demonstrate that the non-solvated form converts to an "apparent" amorphous form (dissolved drug) due to drug dissolution with no appearance of the hemi-hydrate form during water addition stage. The extent of conversion of the non-solvated form was governed by the amount of water added and the rate of conversion was accelerated at higher temperatures. Interestingly, in the wet massing zone, the formation of the hemi-hydrate form was observed at a rate equivalent to the rate of depletion of the non-solvated form with no change in the level of the "apparent amorphous" form generated. The level of hemi-hydrate increased with an increase in wet massing time. The drying process had a significant effect on the proportion of each form. During tray drying, changes in drug form continued for hours. In contrast fluid bed drying appeared to lock the final proportions of drug form product attained during granulation, with comparatively small changes observed during drying. In conclusion, it was possible to simultaneously monitor the three forms in real time during wet granulation and drying using online Raman spectroscopy. The results regarding the effect of process parameters on the degree of transformation are critical for designing a robust process that ensures a consistent form in the final drug product.


Subject(s)
Delayed-Action Preparations/chemistry , Drug Compounding/methods , Solvents/chemistry , Spectrum Analysis, Raman/methods , Calibration , Chemistry, Pharmaceutical , Crystallization , Desiccation , Drug Compounding/instrumentation , Least-Squares Analysis , Particle Size , Spectroscopy, Near-Infrared/instrumentation , Spectroscopy, Near-Infrared/methods , Spectrum Analysis, Raman/instrumentation , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...